Antithrombotic Therapy


The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.

ESC Congress 2021: Top Trials Slideshow

August 31, 2021

Every year, ESC Congress provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for new trials from ESC Congress 2021 conference includes EMPEROR-Preserved, FIGARO-DKD, SSaSS, MASTER DAPT, and the LOOP Study.

FDA Approves Rivaroxaban for Use After Lower Extremity Revascularization in Peripheral Artery Disease

August 24, 2021

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

In High-Risk Patients, Most DOACs Reduce Stroke Risk Without Increasing Bleeding Risk vs Warfarin

August 16, 2021

Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.

Cardiology Month in Review: July 2021

July 31, 2021

July's month in review features stories related to EMPEROR-Preserved meeting primary endpoint, a Q&A with Javed Butler, MD, on heart failure prevention, comparing ACEs vs ARBs, and more. Check back around the end of each month for the next Cardiology Month in Review.